Zacks Investment Research
04 Sept 2026, 15:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
AbbVie's phase III CERVINO study for etentamig in relapsed/refractory multiple myeloma met its primary goals, showing significant improvements in objective response rate (ORR) and progression-free survival (PFS). — Positive phase III data for a pipeline candidate in a high-need oncology indication typically drives valuation increases for the developer.
+0.60Etentamig demonstrated a 74% objective response rate compared to 45.7% for standard available therapies and reduced the risk of disease progression or death by 60%. — The magnitude of efficacy improvement over the standard of care increases the probability of regulatory approval and market adoption.
+0.40The etentamig treatment showed a manageable safety profile with low rates of cytokine release syndrome and fatal infections. — Low toxicity and manageable side effects are critical for the commercial viability of bispecific T-cell engagers.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The prespecified statistical boundary for overall survival had not been crossed at the data cutoff date, despite an 87.9% survival rate versus 72% for standard therapy. — Failure to hit a statistical boundary for overall survival is a slight negative nuance in an otherwise positive data set.
-0.10Which stocks this story touches
The company reported positive phase III data for its pipeline candidate etentamig, meeting primary goals for response rate and progression-free survival.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
2h ago
